Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech announces that Phase III CLL11 study meets primary endpoint

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Eribulin shows increased benefit among women sharing certain traits

Eribulin shows increased benefit among women sharing certain traits